JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB245655

Anti-E2F7 antibody

0

(1 Review)

|

(3 Publications)

Rabbit Polyclonal E2F7 antibody. Suitable for IP and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human Transcription factor E2F7 aa 1-50.

View Alternative Names

Transcription factor E2F7, E2F-7, E2F7

1 Images
Immunoprecipitation - Anti-E2F7 antibody (AB245655)
  • IP

Supplier Data

Immunoprecipitation - Anti-E2F7 antibody (AB245655)

E2F7 was immunoprecipitated from HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg per IP reaction; 20% of IP loaded).

ab245655 used for IP at 6 μg/mg lysate. For WB another anti-E2F7 antibody was used at 1 μg/ml.

Lane 1 : ab245655 IP in HeLa whole cell lysate.
Lane 2 : Control IgG in HeLa whole cell lysate.

Chemiluminescence detection : 30 seconds.

All lanes:

Immunoprecipitation - Anti-E2F7 antibody (ab245655)

Predicted band size: 99 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IP

applications

Immunogen

Synthetic Peptide within Human Transcription factor E2F7 aa 1-50. The exact immunogen used to generate this antibody is proprietary information.

Q96AV8

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "2-5 µg/mg of lysate", "IP-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
ab245655 was affinity purified using an epitope specific to E2F7 immobilized on solid support.
Storage buffer
pH: 7 - 8 Preservative: 0.09% Sodium azide Constituents: Tris citrate/phosphate
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

E2F7 also known simply as E2F transcription factor 7 is a member of the E2F family of transcription factors. It has a unique structure compared to other E2F members lacking the DP dimerization domain. It has a molecular weight of approximately 88 kDa. E2F7 is highly expressed in various tissues including the placenta lung and kidney. This transcription factor binds to DNA and represses the transcription of target genes often acting in the G1/S transition of the cell cycle.
Biological function summary

E2F7 plays a significant role in the maintenance of cellular homeostasis. It does not rely on dimerization for DNA binding distinguishing it from other E2F proteins. E2F7 typically forms a complex with other E2F family proteins to regulate cell cycle checkpoints and control the DNA damage response. It acts as a transcriptional repressor contributing to the regulation of genes essential for DNA replication and repair.

Pathways

E2F7 is integral to the cell cycle and p53 signaling pathways. It plays a role in controlling cell proliferation by repressing genes involved in the transition from the G1 to the S phase of the cell cycle. E2F7 interacts with proteins such as p21 and p53 which are critical in cell cycle arrest and response to DNA damage. The pathway involvement highlights its part in adjusting cellular activities in response to genomic stress and maintaining genomic integrity.

E2F7 has connections to cancer and cardiovascular diseases. Dysregulated expression of E2F7 is often observed in several types of cancer linking it to tumor progression and the modulation of genes such as p53 and p21 that are vital for controlling cell division and apoptosis. In cardiovascular diseases aberrant expression patterns may affect vascular smooth muscle cell proliferation and contribute to atherosclerosis. The involvement of E2F7 highlights its potential as a therapeutic target in these conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Atypical E2F transcription factor that participates in various processes such as angiogenesis, polyploidization of specialized cells and DNA damage response. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'-TTTC[CG]CGC-3'. Directly represses transcription of classical E2F transcription factors such as E2F1. Acts as a regulator of S-phase by recognizing and binding the E2-related site 5'-TTCCCGCC-3' and mediating repression of G1/S-regulated genes. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Also involved in DNA damage response : up-regulated by p53/TP53 following genotoxic stress and acts as a downstream effector of p53/TP53-dependent repression by mediating repression of indirect p53/TP53 target genes involved in DNA replication. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator : associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene. Acts as a negative regulator of keratinocyte differentiation.
See full target information Transcription factor E2F7

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

The Journal of biological chemistry 299:104677 PubMed37028765

2023

VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner.

Applications

Unspecified application

Species

Unspecified reactive species

Zi-Qi Zheng,Zhuo-Hui Huang,Ye-Lin Liang,Wei-Hong Zheng,Cheng Xu,Zhi-Xuan Li,Na Liu,Pan-Yang Yang,Ying-Qin Li,Jun Ma,Ying Sun,Ling-Long Tang,Denghui Wei

Cell reports. Medicine 4:100937 PubMed36787737

2023

Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Brittiny Dhital,Sandra Santasusagna,Perumalraja Kirthika,Michael Xu,Peiyao Li,Marc Carceles-Cordon,Rajesh K Soni,Zhuoning Li,Ronald C Hendrickson,Matthew J Schiewer,William K Kelly,Cora N Sternberg,Jun Luo,Amaia Lujambio,Carlos Cordon-Cardo,Monica Alvarez-Fernandez,Marcos Malumbres,Haojie Huang,Adam Ertel,Josep Domingo-Domenech,Veronica Rodriguez-Bravo

Head & face medicine 17:7 PubMed33637098

2021

Identification of E2F transcription factor 7 as a novel potential biomarker for oral squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Zhou,Lei Xiao,Xiaonan Xu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com